NEW YORK (GenomeWeb News) — Omicia has been awarded a $788,517 Phase II Small Business Innovation Research grant from the National Human Genome Research Institute to help it refine its disease marker genome-annotation system, the firm said today.
 
According to Omicia, the goal of the project is  to “facilitate the development of diagnostic profiles for a diverse array of disease conditions.”
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.